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Introduction
The ASCOT trial is designed to provide important information for treatment of patients with hypertension and hypercholesterolaemia. The economic consequences of alternative therapies, as studied in ASCOT, may be significant, and information about these consequences is important for development of treatment guidelines and for prescription decisions. Therefore a cost-effectiveness analysis based on data from ASCOT is planned. The rationale for and design of this study is described in another paper in this volume. 1 This sub-study provides information for an extension of this cost-effectiveness study to include indirect costs and to adjust life years gained for quality of life (utility). Thus cost-effectiveness can be calculated both with and without indirect costs and both as cost per life year gained and cost per quality-adjusted life year (QALY) gained. 2 This makes it possible to compare the results with similar studies of the cost-effectiveness of treatment of hypertension and hypercholesterolaemia. 3, 4 Background and rationale for the study The recommended methodology for economic evaluations in health care, and the 'gold standard' for cost-effectiveness studies in preventive cardiology, is to present the result as cost per (qualityadjusted) life year gained. The ASCOT study collects data on resource utilisation that can be used Correspondence: Prof NR Poulter, Cardiovascular Studies Unit, Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Campus, London W2 1PG, UK. E-mail: n.poulterȰic.ac.uk for calculations of the direct health care costs associated with the different treatment arms. The study also will give data on the number of cardiac events, for example non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD), which can be used directly as outcome measure in a cost-effectiveness study presenting results as cost per event avoided. These data can also be used for calculation of the number of life years gained as a result of the reduction in events.
However, two types of data are missing in order to be able to present a full cost-effectiveness analysis. For costs, the main study will not provide information on the loss of productivity due to cardiac events. These indirect costs are of the same magnitude, as the direct costs needed for treatment and rehabilitation. Results from a cost-effectiveness analysis based on the 4S trial, 4 showed that the indirect costs the year following a cardiovascular event was 69 100 SEK for patients 35-49 years old and 37 800 for patients 50-64 years of age. This can be compared with direct health care costs of 57 600 SEK. For the second and following year after the event the indirect costs was 33 500 SEK and 22 900 SEK respectively compared to 7900 SEK in direct costs. The omission of these costs will ignore an important benefit of treatment of hypertension and hyperlipidaemia in patients below retirement age.
For outcome, the main study will not provide any information for quality-adjustment of life expectancy. That means that it is not possible to provide decision-makers with information about cost per quality adjusted life years gained. Quality-adjustment has two effects that go in opposite directions. First, it takes into account that not all life years gained are of full health, thus reducing the number of life years gained. Second, it takes into account benefits from avoidance of non-fatal events, which increases the number of life years gained. The cost per quality-adjusted life year gained can thus be either lower or higher than the cost per unadjusted life years gained.
We propose to undertake a sub-study on Swedish ASCOT patients in order to gain information on indirect cost and quality of life changes that can be used to model the social cost per quality-adjusted life years gained in the ASCOT study.
Objectives
(1) To generate study (ASCOT)-specific data on changes in utilities due to validated non-fatal myocardial infarctions. This information will be used in quality adjustment of life years gained in the cost-effectiveness analysis from a societal perspective (2) To generate study (ASCOT)-specific data on labour force participation (days off work) due to validated non-fatal myocardial infarctions. This information will be used in estimating indirect costs in the cost-effectiveness analysis based on a societal perspective.
Study methods and design
Information about indirect costs and quality of life will be collected from a sub-sample of ASCOT patients in Sweden. A questionnaire will be distributed to patients who have had an event. Although it may have been an advantage to collect information regularly for all patients, the amount of data collection involved makes such an approach not practical. Data will be collected through a questionnaire in two parts. Part I asks for information about work participation and part II for information about quality of life. Both questionnaires are very simple, and take less than 5 minutes to complete.
The questionnaires should be completed no later than 3 months after the event had occurred and after 6 and 12 months. A total of three questionnaires should thus be answered. The reasons for doing more than one assessment are that costs and quality of life change over time after the event and onwards. This study will estimate the loss of production and quality of life during the first year after event. The observation at 12 months for labour force participation and quality of life will be carried forward as a proxy for future years.
For work participation, the patient will be asked if he/she works or not; if the answer is yes, the follow-up question is if it is full time or part time. The answers will be used to calculate the loss of production in terms of 'full time employment' equivalents. Costing will be performed, by multiplying the loss in full time equivalents with the average annual productivity. For quality of life, a well-tested instrument, EQ-5D, will be used. 5 This instrument consists of two parts, a descriptive part and a VAS, where the patients mark his present health state. From this instrument, two different utility values can be calculated for the year following an event; one based on the descriptive part and based on the general public's value assessment for different health states and one based on the patients' assessment through the VAS. These utility values will be used for quality adjustment of life years gained in the model of cost-effectiveness. The gain in qualityadjusted life expectancy is determined by the difference in 'utility' before and after an event.
The number of patients required for this sub-study will be determined based on total number of reported CHD events that is required to include 50 patients in the potential workforce, ie, patients Ͻ65 years, who have experienced a verified/confirmed non-fatal MI. The sample size is calculated based on a previous Swedish observational study on the costs of coronary heart disease and stroke. 6 The annual indirect costs for 12 patients with acute MI was 211 500 (s.d. 72 452) SEK before the infarction and 109 208 (92 636) the year after the event, a difference of 102 292 (s.d. 93 023) SEK. The average age was 56 years, and one-quarter of the subjects in the study were women.
The total number of reported CHD events required will be calculated based on the following variables, share of patients Ͻ65 years, share of MI of all nonfatal CHD, rate of fatal events, and verified/ confirmed CHD events to reported CHD (any) events (see Figure 1) . Preliminary estimates indicate that about 35% of patients with a reported CHD event will be under 65 years of age, and some 80% of these events are non-fatal. If 90% of the reported events are confirmed, we need about 200 reported events with non-fatal MI or fatal CHD.
Furthermore, a control group will be included, predominantly to control for recall bias possibilities regarding the assessment of utilities before the CHD event. The control group will be recruited randomly and include 10% of the Swedish study population.
Discussion
Since patients are selected after an event, we must ask about labour force participation and quality of life before the event. For labour force participation, it is probably a small problem. With quality of life it may be problematic to fill in a questionnaire for the state 'before event'. However, previous studies have shown that the recall bias is not a great problem. 7 Also, it may be possible to use population weights as a proxy for pre-event state, if this turns out to be a problem. Re-call bias will be tested by comparing to the control group, but also by comparing the utility values from the questionnaires with age and sex adjusted population values from a recently published Swedish study.
8 Figure 1 Decision tree to calculate the number of reported events that are needed to achieve 50 patients Ͻ65 years. Probability estimates are required at each chance node.
